Back to top
more

Lucid Diagnostics (LUCD)

(Real Time Quote from BATS)

$1.00 USD

1.00
569,291

-0.02 (-1.96%)

Updated Aug 5, 2025 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Mesa Labs (MLAB) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of -5.69% and -2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of +2.86% and +1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -77.78% and 36.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

908 Devices Inc. (MASS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

908 Devices (MASS) delivered earnings and revenue surprises of 18.52% and 2.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of 0% and 6.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IRadimed (IRMD) Lags Q1 Earnings Estimates

by Zacks Equity Research

iRadimed (IRMD) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -26.67% and 14.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of -80% and 9.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 109.09% and 18.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -76% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 24.14% and 1.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lucid Inks New Partnership With VITALExam: Stock to Gain?

by Zacks Equity Research

LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.

Zacks Equity Research

Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Neuronetics (STIM) delivered earnings and revenue surprises of -26.09% and 3.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stereotaxis Inc. (STXS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis (STXS) delivered earnings and revenue surprises of -60% and 35.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RxSight, Inc. (RXST) Reports Break-Even Earnings for Q3

by Zacks Equity Research

RxSight (RXST) delivered earnings and revenue surprises of -100% and 0.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avanos Medical (AVNS) Q3 Earnings Meet Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of 0% and 2.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data

by Zacks Equity Research

Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.